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Background
The efficiency and safety of the thiopurine therapy rely on
the concentration of patient's cytotoxic thioguanine
nucleotides (TGN), which in turn depend on the deactiva-
tion of thiopurine drugs by thiopurine S-methyltrans-
ferase (TPMT). The activity of TPMT largely depends on
the presence of genetic polymorphisms. Determination of
mutations in the TPMT gene before starting 6-mercaptop-
urine (6-MP) therapy represents a quick, simple and cost-
effective strategy to individualize thiopurine dosing.
However, TPMT phenotype-to-genotype correlation is not
complete, indicating a need for identification of novel
biomarkers. The prime candidate is S-adenosylmethio-
nine (SAM) which by binding into the active site of TPMT
stabilizes its structure and consequently influences the
metabolism and toxicity of thiopurine drugs [1].
Methods
6-MP-induced cytotoxicity was studied in MOLT cells.
Metabolic activity of cells was determined by the CellTiter
Aqueous One Proliferation Assay. Cytosolic TGN, SAM
and methylthioinosine monophosphate (MeTIMP) levels
as well as TPMT activity were measured by the modified
reverse-phase HPLC method. Intracellular ATP levels were
determined by the CellTiter Glo Luminescent Cell Viabil-
ity Assay (Promega). Apoptotic cells were detected by the
Annexin V-FITC Apoptosis Detection Kit (Sigma) and vis-
ualized by fluorescence microscopy. Caspase-3 activity
was measured using labeled DEVD substrate.
Results
We herein present evidence of a novel TPMT-mediated
mechanism of SAM-specific effects on 6-MP-induced cyto-
toxicity [2]. Our results show that exogenous SAM rescues
cells from the toxic effects of 6-MP by restoring cell prolif-
eration and delaying the onset of apoptosis. This is
achieved by altering the dynamics of 6-MP metabolism,
resulting in lower production of TGNs and MeTIMP. We
prove that the extent of MeTIMP-induced inhibition of de
novo purine synthesis (DNPS) determines the concentra-
tions of intracellular ATP, and consequently SAM, which
acts as a positive modulator of TPMT activity. This leads to
a greater conversion of 6-MP to inactive 6-methylmercap-
topurine, and lower availability of thioinosine mono-
phosphate for the biotransformation to TGNs and
MeTIMP. By acting as a TPMT-stabilizing factor, the avail-
ability of SAM contributes to the extent of 6-MP cytotox-
icity.
Conclusion
By identifying SAM as an important modulator of TPMT
activity and consequently thiopurine toxicity, novel
rationalization of the therapy may apply.
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